Research Papers

25 of 406 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients wit…
Gyöngyösi M; Lukovic D; Mester-Tonczar J; Zlabinger K; Einzinger P; Spannbauer A; Schweiger V; Schefberger K; Samaha E; Bergler-Klein J; Riesenhuber M; Nitsche C; Hengstenberg C; Mucher P; Haslacher H; Breuer M; Strassl R; Puchhammer-Stöckl E; Loewe C; Beitzke D; Hasimbegovic E; Zelniker TA.
NPJ Vaccines (Unknown)
Published: 2023
4/6 Transparent
Registered Funding Declared
A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates.
Fowler A; Van Rompay KKA; Sampson M; Leo J; Watanabe JK; Usachenko JL; Immareddy R; Lovato DM; Schiller JT; Remaley AT; Chackerian B.
NPJ Vaccines (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Vaccination of cattle with the Babesia bovis sexual-stage protein HAP2 abrogates parasite transmission by Rhipicephalus…
Silva MG; Bastos RG; Laughery JM; Alzan HF; Rathinasamy VA; Cooke BM; Suarez CE.
NPJ Vaccines (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Deglycosylation of eukaryotic-expressed flagellin restores adjuvanticity.
Khim K; Puth S; Radhakrishnan K; Nguyen TD; Lee YS; Jung CH; Lee SE; Rhee JH.
NPJ Vaccines (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Update on the development of Group A Streptococcus vaccines.
Ajay Castro S; Dorfmueller HC.
NPJ Vaccines (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELD<sup>TM</sup> and COVAXIN<…
Rakshit S; Babji S; Parthiban C; Madhavan R; Adiga V; J SE; Chetan Kumar N; Ahmed A; Shivalingaiah S; Shashikumar N; V M; Johnson AR; Ramesh N; B RG; Asokan M; Mayor S; Kang G; D'souza G; Dias M; Vyakarnam A.
NPJ Vaccines (Unknown)
Published: 2023
4/6 Transparent
Registered Funding Declared
Ensuring equity with pre-clinical planning for chlamydia vaccines.
Collar AL; Clarke TN; Jamus AN; Frietze KM.
NPJ Vaccines (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
A next-generation GMMA-based vaccine candidate to fight shigellosis.
Rossi O; Citiulo F; Giannelli C; Cappelletti E; Gasperini G; Mancini F; Acquaviva A; Raso MM; Sollai L; Alfini R; Aruta MG; Vitali CG; Pizza M; Necchi F; Rappuoli R; Martin LB; Berlanda Scorza F; Colucci AM; Micoli F.
NPJ Vaccines (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Identifying a causal link between prolactin signaling pathways and COVID-19 vaccine-induced menstrual changes.
Hajjo R; Momani E; Sabbah DA; Baker N; Tropsha A.
NPJ Vaccines (Unknown)
Published: 2023
5/6 Transparent
Data Code Funding Declared
An anti-LpqH human monoclonal antibody from an asymptomatic individual mediates protection against Mycobacterium tuberc…
Krishnananthasivam S; Li H; Bouzeyen R; Shunmuganathan B; Purushotorman K; Liao X; Du F; Friis CGK; Crawshay-Williams F; Boon LH; Xinlei Q; Chan CEZ; Sobota R; Kozma M; Barcelli V; Wang G; Huang H; Floto A; Bifani P; Javid B; MacAry PA.
NPJ Vaccines (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin<sup>®…
Singh C; Verma S; Reddy P; Diamond MS; Curiel DT; Patel C; Jain MK; Redkar SV; Bhate AS; Gundappa V; Konatham R; Toppo L; Joshi AC; Kushwaha JS; Singh AP; Bawankule S; Ella R; Prasad S; Ganneru B; Chiteti SR; Kataram S; Vadrevu KM.
NPJ Vaccines (Unknown)
Published: 2023
5/6 Transparent
Data Registered Funding Declared
Emerging vaccine strategies against the incessant pneumococcal disease.
Duke JA; Avci FY.
NPJ Vaccines (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Screening of immunogenic proteins and evaluation of vaccine candidates against Mycoplasma synoviae.
Zhang G; Han L; Li Z; Chen Y; Li Q; Wang S; Shi H.
NPJ Vaccines (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
C5aR<sup>+</sup> dendritic cells fine-tune the Peyer's patch microenvironment to induce antigen-specific CD8<sup>+</sup…
Kim SH; Shim EH; Kim DJ; Jang YS.
NPJ Vaccines (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
The need for a clinical case definition in test-negative design studies estimating vaccine effectiveness.
Sullivan SG; Khvorov A; Huang X; Wang C; Ainslie KEC; Nealon J; Yang B; Cowling BJ; Tsang TK.
NPJ Vaccines (Unknown)
Published: 2023
4/6 Transparent
Code Funding Declared
Optimization of an alum-anchored clinical HIV vaccine candidate.
Rodrigues KA; Cottrell CA; Steichen JM; Groschel B; Abraham W; Suh H; Agarwal Y; Ni K; Chang JYH; Yousefpour P; Melo MB; Schief WR; Irvine DJ.
NPJ Vaccines (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
A Strep A vaccine global demand and return on investment forecast to inform industry research and development prioritiz…
Walkinshaw DR; Wright MEE; Williams M; Scarapicchia TMF; Excler JL; Wiley RE; Mullin AE.
NPJ Vaccines (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Multifunctional IgG/IgM antibodies and cellular cytotoxicity are elicited by the full-length MSP1 SumayaVac-1 malaria v…
Rosenkranz M; Fürle K; Hibbert J; Ulmer A; Ali A; Giese T; Blank A; Haefeli WE; Böhnlein E; Lanzer M; Thomson-Luque R.
NPJ Vaccines (Unknown)
Published: 2023
5/6 Transparent
Data Registered Funding Declared
A human antibody epitope map of the malaria vaccine antigen Pfs25.
Shukla N; Tang WK; Coelho CH; Long CA; Healy SA; Sagara I; Miura K; Duffy PE; Tolia NH.
NPJ Vaccines (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants.
Springer DN; Bauer M; Medits I; Camp JV; Aberle SW; Burtscher C; Höltl E; Weseslindtner L; Stiasny K; Aberle JH.
NPJ Vaccines (Unknown)
Published: 2023
2/6 Transparent
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.
Lyke KE; Atmar RL; Dominguez Islas C; Posavad CM; Deming ME; Branche AR; Johnston C; El Sahly HM; Edupuganti S; Mulligan MJ; Jackson LA; Rupp RE; Rostad CA; Coler RN; Bäcker M; Kottkamp AC; Babu TM; Dobrzynski D; Martin JM; Brady RC; Frenck RW; Rajakumar K; Kotloff K; Rouphael N; Szydlo D; PaulChoudhury R; Archer JI; Crandon S; Ingersoll B; Eaton A; Brown ER; McElrath MJ; Neuzil KM; Stephens DS; Post DJ; Lin BC; Serebryannyy L; Beigel JH; Montefiori DC; Roberts PC; DMID 21-0012 Study Group.
NPJ Vaccines (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Availability and use of Standards in vaccine development.
Avumegah MS; Mattiuzzo G; Särnefält A; Page M; Makar K; Lathey J; Kim J; Yimer SA; Craig D; Knezevic I; Bernasconi V; Kristiansen PA; Kromann I.
NPJ Vaccines (Unknown)
Published: 2023
2/6 Transparent
Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice.
Jangra S; Landers JJ; Laghlali G; Rathnasinghe R; Warang P; Park SC; O'Konek JJ; Singh G; Janczak KW; García-Sastre A; Arya N; Karadag D; Baker JR; Schotsaert M; Wong PT.
NPJ Vaccines (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
A chimeric vaccine protects farmed saltwater crocodiles from West Nile virus-induced skin lesions.
Habarugira G; Harrison JJ; Moran J; Suen WW; Colmant AMG; Hobson-Peters J; Isberg SR; Bielefeldt-Ohmann H; Hall RA.
NPJ Vaccines (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
A pilot metabolomic study of drug interaction with the immune response to seasonal influenza vaccination.
Siddiqa A; Wang Y; Thapa M; Martin DE; Cadar AN; Bartley JM; Li S.
NPJ Vaccines (Unknown)
Published: 2023
5/6 Transparent
Data Registered Funding Declared